News | Thrombectomy Devices | September 24, 2024

FDA Gives Clearance for Drug to Treat Thrombotic Diseases

Thrombolytic Science announces FDA’s IND clearance of Mutant Prourokinase for treatment of thrombotic diseases


Sept. 24, 2024 — Thrombolytic Science, LLC (TSI) has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme. A U.S.-based clinical trial will further confirm the safety and tolerability of TSI's novel mutant prourokinase (mproUK) in healthy volunteers.

“We are thrilled to achieve this important milestone with the FDA clearance for our first U.S. clinical trial of mproUK,” said Alexis C. Wallace, MSc. Eng., MBA, CEO of TSI. “Our innovative approach to fibrinolytic therapy has the potential to transform the treatment landscape for life-threatening thrombotic conditions, offering patients a faster, safer, and more effective reperfusion option. Following promising Phase II results from the DUMAS trial in stroke patients in the Netherlands, we’re now advancing to a Phase II trial in the UK for myocardial infarction following MHRA approval. This IND clearance is a significant step toward expanding access to our low-dose fibrinolytic treatment for broader patient populations globally."

In the natural, physiological mechanism of clot lysis, while tissue plasminogen activator (tPA) initiates clot lysis, prourokinase completes the dissolution of the fibrin clot.

"This difference is comparable to the starter of a car and its engine.  tPA is like the starter, whereas prourokinase is the engine”, explained Victor Gurewich, MD, TSI co-founder and discoverer of prourokinase "Physiological fibrinolysis requires a mini bolus of r-tPA followed by an infusion of a low dose of mproUK. In recent clinical studies, this treatment has been shown to be free of bleeding risk and rethrombosis while having the potential to re-establish blood flow earlier and being more cost effective than in-hospital surgical solutions.”

This treatment is based on the natural, biological clot dissolving mechanism involving the sequence of tPA and prourokinase, the latter having been stabilized by a single site mutation. This mutation has significantly improved the safety of prourokinase without interfering with its biological clot lysing mechanism of action.  A successful proof of concept clinical trial using native prourokinase in heart attack patients, preceded by a mini dose of tPA was previously published, the PATENT trial. More recently, promising results were obtained with mutant proUK in ischemic stroke patients, the DUMAS trial.

For more information, visit www.tsillc.net

 


Related Content

News | Thrombectomy Devices

Sept. 5, 2024 - Prolocor, Inc. and Slingshot Biosciences recently announced the publication in Bioanalysis of the ...

Home September 10, 2024
Home
News | Thrombectomy Devices

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

Home January 16, 2024
Home
Feature | Thrombectomy Devices | By Global Market Insights

The global thrombectomy devices market is poised to experience substantial expansion, owing to the emergence of ...

Home June 27, 2022
Home
News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
Home
News | Thrombectomy Devices

November 12, 2021 — Penumbra Inc. announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter ...

Home November 12, 2021
Home
News | Thrombectomy Devices

January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...

Home January 08, 2021
Home
News | Thrombectomy Devices

September 25, 2020 — Philips Healthcare launched its QuickClear mechanical thrombectomy system. The compact, single-use ...

Home September 25, 2020
Home
Technology | Thrombectomy Devices

July 25, 2019 — Penumbra announced U.S. commercial availability of the Penumbra System’s most advanced technology, the ...

Home July 25, 2019
Home
News | Thrombectomy Devices

February 12, 2019 — A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology ...

Home February 12, 2019
Home
News | Thrombectomy Devices

February 5, 2019 — Stroke survivors have better quality of life three months after their stroke if the clot that caused ...

Home February 05, 2019
Home
Subscribe Now